On a Mission to Expand Access to Mitral Valve Therapy

Nyra Medical is a clinical-stage medical device company pioneering a new era in structural heart care. Our mission is to improve and extend the lives of patients with valvular heart disease by delivering elegant, transcatheter solutions that restore valve function while preserving natural physiology.

We are focused on solving one of cardiology’s most urgent challenges: treating functional (secondary) mitral regurgitation (FMR) in heart failure patients who are not candidates for current therapies. Nyra is investigating treatment of Ventricular FMR (Type IIIb – central and commissure), and Atrial FMR (Type 1A) anatomical etiologies in our clinical trials. Our proprietary technology — the Cardiac Leaflet Enhancer, or CARLEN — is designed to address this unmet need through a sutureless, single-leaflet device that augments native valve anatomy without altering flow dynamics or precluding future interventions.